Immunogenetics: Open Access
Open Access

Abstract

Passive Immunotherapy Using Approved Vaccines for the Management the Evolving Fast Spreading SARS Cov-2 Variants: A Personal Viewpoint from the UK Perspectives

Jerard Seghatchian*

The current use of the IT tools, so called, Artificial Intelligence in the procedural, patterns and large data analyses have proven to be extremely useful in establishing some newer generation of drug therapy. This manuscript aimed to provide an update on the current status of passive immunotherapy, using the two currently approved vaccines that appear to provide a balance amount of CoV-2 neutralizing antibodies, after 3-4 weeks to individuals in need for either preventative or therapeutic intervention.

Published Date: 2021-03-10; Received Date: 2021-02-17